275 related articles for article (PubMed ID: 15282268)
1. Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior.
Marti M; Mela F; Veronesi C; Guerrini R; Salvadori S; Federici M; Mercuri NB; Rizzi A; Franchi G; Beani L; Bianchi C; Morari M
J Neurosci; 2004 Jul; 24(30):6659-66. PubMed ID: 15282268
[TBL] [Abstract][Full Text] [Related]
2. Endogenous nociceptin/orphanin FQ (N/OFQ) contributes to haloperidol-induced changes of nigral amino acid transmission and parkinsonism: a combined microdialysis and behavioral study in naïve and nociceptin/orphanin FQ receptor knockout mice.
Mabrouk OS; Marti M; Morari M
Neuroscience; 2010 Mar; 166(1):40-8. PubMed ID: 20006677
[TBL] [Abstract][Full Text] [Related]
3. Stimulation of δ opioid receptor and blockade of nociceptin/orphanin FQ receptor synergistically attenuate parkinsonism.
Mabrouk OS; Viaro R; Volta M; Ledonne A; Mercuri N; Morari M
J Neurosci; 2014 Sep; 34(39):12953-62. PubMed ID: 25253844
[TBL] [Abstract][Full Text] [Related]
4. Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release.
Marti M; Mela F; Guerrini R; Calò G; Bianchi C; Morari M
J Neurochem; 2004 Dec; 91(6):1501-4. PubMed ID: 15584926
[TBL] [Abstract][Full Text] [Related]
5. The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA.
Marti M; Trapella C; Morari M
J Neurochem; 2008 Dec; 107(6):1683-96. PubMed ID: 19014386
[TBL] [Abstract][Full Text] [Related]
6. Nociceptin/orphanin FQ modulates motor behavior and primary motor cortex output through receptors located in substantia nigra reticulata.
Marti M; Viaro R; Guerrini R; Franchi G; Morari M
Neuropsychopharmacology; 2009 Jan; 34(2):341-55. PubMed ID: 18418358
[TBL] [Abstract][Full Text] [Related]
7. Nociceptin/orphanin FQ receptors modulate glutamate extracellular levels in the substantia nigra pars reticulata. A microdialysis study in the awake freely moving rat.
Marti M; Guerrini R; Beani L; Bianchi C; Morari M
Neuroscience; 2002; 112(1):153-60. PubMed ID: 12044480
[TBL] [Abstract][Full Text] [Related]
8. [(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor.
Carrà G; Rizzi A; Guerrini R; Barnes TA; McDonald J; Hebbes CP; Mela F; Kenigs VA; Marzola G; Rizzi D; Gavioli E; Zucchini S; Regoli D; Morari M; Salvadori S; Rowbotham DJ; Lambert DG; Kapusta DR; Calo' G
J Pharmacol Exp Ther; 2005 Mar; 312(3):1114-23. PubMed ID: 15509719
[TBL] [Abstract][Full Text] [Related]
9. Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson's disease: a behavioral and neurochemical study in reserpinized mice.
Volta M; Mabrouk OS; Bido S; Marti M; Morari M
J Neurochem; 2010 Dec; 115(6):1543-55. PubMed ID: 20950413
[TBL] [Abstract][Full Text] [Related]
10. Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity.
Volta M; Viaro R; Trapella C; Marti M; Morari M
Exp Neurol; 2011 Mar; 228(1):126-37. PubMed ID: 21215744
[TBL] [Abstract][Full Text] [Related]
11. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.
Witkin JM; Statnick MA; Rorick-Kehn LM; Pintar JE; Ansonoff M; Chen Y; Tucker RC; Ciccocioppo R
Pharmacol Ther; 2014 Mar; 141(3):283-99. PubMed ID: 24189487
[TBL] [Abstract][Full Text] [Related]
12. Endogenous nociceptin/orphanin FQ signalling produces opposite spinal antinociceptive and supraspinal pronociceptive effects in the mouse formalin test: pharmacological and genetic evidences.
Rizzi A; Nazzaro C; Marzola GG; Zucchini S; Trapella C; Guerrini R; Zeilhofer HU; Regoli D; Calo' G
Pain; 2006 Sep; 124(1-2):100-8. PubMed ID: 16697109
[TBL] [Abstract][Full Text] [Related]
13. NOP Receptor Ligands and Parkinson's Disease.
Mercatelli D; Pisanò CA; Novello S; Morari M
Handb Exp Pharmacol; 2019; 254():213-232. PubMed ID: 30689087
[TBL] [Abstract][Full Text] [Related]
14. Activation of nociceptin/orphanin FQ-NOP receptor system inhibits tyrosine hydroxylase phosphorylation, dopamine synthesis, and dopamine D(1) receptor signaling in rat nucleus accumbens and dorsal striatum.
Olianas MC; Dedoni S; Boi M; Onali P
J Neurochem; 2008 Oct; 107(2):544-56. PubMed ID: 18717817
[TBL] [Abstract][Full Text] [Related]
15. [Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor.
Calo G; Rizzi A; Rizzi D; Bigoni R; Guerrini R; Marzola G; Marti M; McDonald J; Morari M; Lambert DG; Salvadori S; Regoli D
Br J Pharmacol; 2002 May; 136(2):303-11. PubMed ID: 12010780
[TBL] [Abstract][Full Text] [Related]
16. The nociceptin receptor antagonist [Nphe1,Arg14,Lys15]nociceptin/orphanin FQ-NH2 blocks the stimulatory effects of nociceptin/orphanin FQ on the HPA axis in rats.
Leggett JD; Harbuz MS; Jessop DS; Fulford AJ
Neuroscience; 2006 Sep; 141(4):2051-7. PubMed ID: 16784820
[TBL] [Abstract][Full Text] [Related]
17. Involvement of the neuropeptide nociceptin/orphanin FQ in kainate seizures.
Bregola G; Zucchini S; Rodi D; Binaschi A; D'Addario C; Landuzzi D; Reinscheid R; Candeletti S; Romualdi P; Simonato M
J Neurosci; 2002 Nov; 22(22):10030-8. PubMed ID: 12427860
[TBL] [Abstract][Full Text] [Related]
18. Novel potent agonist [(pF)Phe4,Aib7,Aib11,Arg14,Lys15]N/OFQ-NH2 and antagonist [Nphe1,(pF)Phe4,Aib7,Aib11,Arg14,Lys15]N/OFQ-NH2 of nociceptin/orphanin FQ receptor.
Peng YL; Chang M; Dong SL; Li W; Han RW; Fu GX; Chen Q; Wang R
Regul Pept; 2006 May; 134(2-3):75-81. PubMed ID: 16516988
[TBL] [Abstract][Full Text] [Related]
19. The effects of [Arg14, Lys15] nociceptin/orphanin FQ, a highly potent agonist of the NOP receptor, on in vitro and in vivo gastrointestinal functions.
Broccardo M; Linari G; Guerrini R; Agostini S; Petrella C; Improta G
Peptides; 2005 Sep; 26(9):1590-7. PubMed ID: 16112397
[TBL] [Abstract][Full Text] [Related]
20. The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway.
Marti M; Trapella C; Viaro R; Morari M
J Neurosci; 2007 Feb; 27(6):1297-307. PubMed ID: 17287504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
